- BNR · Nasdaq
- Services-Medical Laboratories
- Guangzhou, Guangdong, China
- CIK 0001792267
Updated from SEC filings through
Top things to know
Executives
- Xiaozhi Hu Senior Director in Finance Form 3, March 17, 2026
Burning Rock Biotech Ltd is a U.S. public company in services-medical laboratories (SIC 8071), headquartered in Guangzhou, Guangdong, China. It trades as BNR on Nasdaq. Revenue was $77.2M in the fiscal year ending December 31, 2025, +9.2% from the year before.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $77.2M 20-F, 2026-04-28 | $70.7M 20-F, 2025-04-29 | $75.7M 20-F, 2024-04-29 | $81.7M 20-F, 2023-04-20 | $79.7M 20-F, 2022-04-29 |
| Operating income | -$7.8M 20-F, 2026-04-28 | -$49.0M 20-F, 2025-04-29 | -$94.3M 20-F, 2024-04-29 | -$142M 20-F, 2023-04-20 | -$125M 20-F, 2022-04-29 |
| SG&A | $41.7M 20-F, 2026-04-28 | $62.0M 20-F, 2025-04-29 | $96.6M 20-F, 2024-04-29 | $136M 20-F, 2023-04-20 | $124M 20-F, 2022-04-29 |
| Net income | -$7.9M 20-F, 2026-04-28 | -$47.5M 20-F, 2025-04-29 | -$92.1M 20-F, 2024-04-29 | -$141M 20-F, 2023-04-20 | -$125M 20-F, 2022-04-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Xiaozhi Hu | Senior Director in Finance | Form 3, March 17, 2026 |
What Burning Rock Biotech Ltd does
We aim to transform precision oncology and early cancer detection. We are China’s leading NGS-based cancer therapy selection company. Our cancer therapy selection platform is built upon our advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Reportable segments | 3 (period ending December 31, 2025) | 20-F, April 28, 2026 |
|---|---|---|
| Auditor | Ernst & Young Hua Ming LLP (Shanghai, the People’s Republic of China) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| June 26, 2026 | Yusheng Han Director | Buy | 731,410 | $6.2M | Form 4, July 2, 2026 |
| March 31, 2026 | Yusheng Han Director | Buy | 314,870 | $5.5M | Form 4, April 2, 2026 |
Recent 8-K events
No 8-K filings on file.
Frequently asked questions about Burning Rock Biotech Ltd
- What does Burning Rock Biotech Ltd do?
- In its own words, from Item 1 of its 10-K: "We aim to transform precision oncology and early cancer detection. We are China’s leading NGS-based cancer therapy selection company. Our cancer therapy selection platform is built upon our advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model."
- What is Burning Rock Biotech Ltd's revenue?
- $77.2M for the fiscal year ending December 31, 2025, from its 20-F filed April 28, 2026.
- Is Burning Rock Biotech Ltd profitable?
- Burning Rock Biotech Ltd reported net income of -$7.9M for the fiscal year ending December 31, 2025.
- Where is Burning Rock Biotech Ltd headquartered?
- Guangzhou, Guangdong, China.
- What is Burning Rock Biotech Ltd's stock ticker?
- BNR on Nasdaq.
- What industry is Burning Rock Biotech Ltd in?
- Services-Medical Laboratories, SIC code 8071.
- What is Burning Rock Biotech Ltd's website?
- brbiotech.com.
- When does Burning Rock Biotech Ltd report earnings next?
- November 19, 2026. Source: pg_future_events.
- Is Burning Rock Biotech Ltd a public company?
- Yes. Burning Rock Biotech Ltd files with the SEC under CIK 0001792267 and trades as BNR.
- Who audits Burning Rock Biotech Ltd?
- Ernst & Young Hua Ming LLP, Shanghai, the People’s Republic of China, as named in its latest annual report (10-K).
- How many business segments does Burning Rock Biotech Ltd report?
- 3 reportable segments for the period ending December 31, 2025, from its 20-F filed April 28, 2026.
- Have Burning Rock Biotech Ltd insiders traded stock recently?
- Since March 31, 2026, officers and directors reported 0 open-market sales and 2 purchases worth about $11.6M on Forms 4 and 5. The most recent: Yusheng Han (Director) bought 731,410 shares on June 26, 2026.